| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia.
|
Blood
|
1980
|
1.18
|
|
2
|
A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969.
|
J Clin Oncol
|
1988
|
1.13
|
|
3
|
Deoxycytidine and deoxythymidine kinase activities in plasma of mice and patients with neoplastic disease.
|
Cancer Res
|
1982
|
1.01
|
|
4
|
Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells.
|
Cancer Res
|
1977
|
1.00
|
|
5
|
Life-threatening complications of empiric ceftriaxone therapy for 'seronegative Lyme disease'.
|
South Med J
|
1991
|
0.99
|
|
6
|
Prophylactic heparin therapy in acute promyelocytic leukemia.
|
Cancer
|
1978
|
0.98
|
|
7
|
Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes.
|
Cancer Treat Rep
|
1983
|
0.97
|
|
8
|
Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.
|
J Clin Invest
|
1990
|
0.96
|
|
9
|
Growth characteristics of leukemic and normal hematopoietic cells in Ph' + chronic myelogenous leukemia and effects of intensive treatment.
|
Blood
|
1982
|
0.94
|
|
10
|
Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
|
Leukemia
|
1992
|
0.90
|
|
11
|
Induction of in vitro proliferation and maturation of human aneuploid myelogenous leukemic cells.
|
J Exp Med
|
1982
|
0.90
|
|
12
|
Lymphoblastic lymphoma in adults.
|
J Clin Oncol
|
1986
|
0.89
|
|
13
|
Specific translocations characterize Burkitt's-like lymphoma of homosexual men with the acquired immunodeficiency syndrome.
|
Blood
|
1983
|
0.87
|
|
14
|
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
|
J Clin Oncol
|
1993
|
0.87
|
|
15
|
Suppression of lymphocyte activation and functions by a leukemia cell-derived inhibitor.
|
Proc Natl Acad Sci U S A
|
1986
|
0.85
|
|
16
|
Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts.
|
Blood
|
1991
|
0.84
|
|
17
|
Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
|
Leukemia
|
1992
|
0.83
|
|
18
|
Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone).
|
Blood
|
1982
|
0.83
|
|
19
|
Malignant lymphomas in a population at risk for acquired immune deficiency syndrome.
|
Cancer
|
1987
|
0.82
|
|
20
|
Acute lymphoblastic leukemia in adults.
|
Semin Oncol
|
1985
|
0.81
|
|
21
|
Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy.
|
Blood
|
1984
|
0.81
|
|
22
|
Male reproductive capacity may recover following drug treatment with the L-10 protocol for acute lymphocytic leukemia.
|
Cancer
|
1984
|
0.81
|
|
23
|
Molecular heterogeneity of adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Cancer Res
|
1988
|
0.81
|
|
24
|
Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABDV and low-dose radiation therapy restricted to originally bulky disease.
|
Cancer Treat Rep
|
1982
|
0.80
|
|
25
|
The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
|
J Clin Invest
|
1991
|
0.80
|
|
26
|
Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia.
|
Am J Hum Genet
|
1989
|
0.80
|
|
27
|
Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response.
|
Cancer Chemother Pharmacol
|
1992
|
0.80
|
|
28
|
The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia.
|
Leukemia
|
1988
|
0.80
|
|
29
|
Elaboration of granulocyte-macrophage colony-stimulating factor by human tumor cell lines and normal urothelium.
|
Exp Hematol
|
1985
|
0.79
|
|
30
|
Oral trimethoprim/sulfamethoxazole in attempt to prevent infection after induction chemotherapy for acute leukemia.
|
Am J Med
|
1984
|
0.79
|
|
31
|
Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced breast cancer.
|
Cancer Chemother Pharmacol
|
1988
|
0.79
|
|
32
|
Selenium status and the polyp-cancer sequence: a colonoscopically controlled study.
|
Am J Gastroenterol
|
1988
|
0.79
|
|
33
|
Proliferative potential of subpopulations of granulocyte-macrophage progenitor cells in normal subjects and chronic myelogenous leukemia patients.
|
Blood
|
1983
|
0.78
|
|
34
|
Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells.
|
Leukemia
|
1987
|
0.78
|
|
35
|
High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
|
Blood
|
1987
|
0.78
|
|
36
|
CML patients in blast crisis have breakpoints localized to a specific region of the BCR.
|
Blood
|
1987
|
0.77
|
|
37
|
Acute nonlymphocytic leukemia following treatment of malignant glioma. Report of two cases.
|
J Neurosurg
|
1984
|
0.77
|
|
38
|
Induction by tumor-promoting phorbol diester of colony-stimulating activity in human myeloid leukemia cells transformed to macrophage-mimicking cells.
|
Cancer Res
|
1981
|
0.77
|
|
39
|
Treatment of patients with HIV thrombocytopenia and hemolytic uremic syndrome with protein A (Prosorba column) immunoadsorption.
|
Semin Hematol
|
1989
|
0.77
|
|
40
|
Deoxycytidine stimulates the in vitro growth of normal CFU-GM and reverses the negative regulatory effects of acidic isoferritin and prostaglandin E1.
|
Blood
|
1986
|
0.77
|
|
41
|
A phase II trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma.
|
Cancer
|
1991
|
0.77
|
|
42
|
Pilot study of all-trans retinoic acid as post-remission therapy in patients with acute promyelocytic leukemia.
|
Leukemia
|
1995
|
0.77
|
|
43
|
Hypercalcemia associated with adenocarcinoma of the rectum. A case report and review of the literature.
|
Anticancer Res
|
1992
|
0.76
|
|
44
|
The karyotype of Philadelphia chromosome-negative, bcr rearrangement-positive chronic myeloid leukemia.
|
Cancer Genet Cytogenet
|
1988
|
0.76
|
|
45
|
Non-T, non-B acute lymphoblastic leukemia (L3) with t(8;22) and two 14q+ chromosomes.
|
Cancer Genet Cytogenet
|
1983
|
0.76
|
|
46
|
A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion.
|
Invest New Drugs
|
1992
|
0.76
|
|
47
|
Two separate differentiation inducing proteins for human myeloid leukemia cells and their isolation from normal lymphocytes.
|
Proc Soc Exp Biol Med
|
1990
|
0.76
|
|
48
|
Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells.
|
Exp Hematol
|
1991
|
0.76
|
|
49
|
Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia.
|
Leukemia
|
1989
|
0.76
|
|
50
|
Treatment of acute nonlymphocytic leukemia in adults: response to 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine and thioguanine on the L-12 protocol.
|
Cancer
|
1981
|
0.76
|
|
51
|
Macrophage-like cell transformation and CFU(c) fluctuations in normal and leukemic human marrow cultures treated by phorbol diester.
|
Biomedicine
|
1979
|
0.76
|
|
52
|
Phenomenon of formation of giant fat-containing cells in human bone marrow cultures induced by human serum factor: normal and leukemic patterns.
|
Proc Natl Acad Sci U S A
|
1983
|
0.75
|
|
53
|
Heterogeneity of cell lineages in L3 leukemias.
|
Blood
|
1980
|
0.75
|
|
54
|
Response of refractory thrombotic thrombocytopenic purpura to extracorporeal immunoadsorption.
|
N Engl J Med
|
1992
|
0.75
|
|
55
|
Hepatic abscess following hepatic arterial infusion chemotherapy with an implantable pump.
|
Cancer Invest
|
1986
|
0.75
|
|
56
|
Philadelphia chromosome and terminal transferase-positive acute leukemia: similarity of terminal phase of chronic myelogenous leukemia and de novo acute presentation.
|
J Clin Oncol
|
1983
|
0.75
|
|
57
|
Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors.
|
Leukemia
|
1991
|
0.75
|
|
58
|
Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells.
|
Leukemia
|
1988
|
0.75
|
|
59
|
Massive lymphadenopathy mimicking lymphoma in leukemic reticuloendotheliosis.
|
Am J Med
|
1979
|
0.75
|
|
60
|
Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells.
|
J Cancer Res Clin Oncol
|
1989
|
0.75
|
|
61
|
Malignant eccrine poroma and isotretinoin.
|
Ann Intern Med
|
1984
|
0.75
|
|
62
|
Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity.
|
Blood
|
1987
|
0.75
|
|
63
|
Relationship of Auer rods and chromosome findings to outcome in eighty-nine adults with acute nonlymphoblastic leukemia.
|
Leuk Res
|
1985
|
0.75
|
|
64
|
Is further intensification of treatment warranted in acute nonlymphoblastic leukemia?
|
Cancer Treat Rep
|
1983
|
0.75
|
|
65
|
Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced head and neck cancer.
|
Invest New Drugs
|
1990
|
0.75
|
|
66
|
The extracerebral dopamine antagonist domperidone block the suppressive effect of bromocriptine on prolactin and TSH secretion in man.
|
Biomedicine
|
1981
|
0.75
|
|
67
|
Induction of giant fat cells in human bone marrow culture by human serum factor.
|
Biomedicine
|
1981
|
0.75
|
|
68
|
The safety and efficacy of gi endoscopy in patients with acute-leukemia - a review of 27 cases.
|
Int J Oncol
|
1992
|
0.75
|
|
69
|
Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.
|
Cancer Treat Rep
|
1983
|
0.75
|
|
70
|
Cellular interactions in hemopoiesis.
|
Blood Cells
|
1987
|
0.75
|
|
71
|
[Comparison of the therapeutic efficacity of 2 induction protocols in acute myeloid leukemia using exact quantification of bone marrow cellularity].
|
Onkologie
|
1983
|
0.75
|
|
72
|
The eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease: a follow-up report.
|
Cancer
|
1980
|
0.75
|
|
73
|
Phase II trial of vindesine in patients with acute leukemia.
|
Cancer Treat Rep
|
1980
|
0.75
|
|
74
|
High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
|
Semin Oncol
|
1987
|
0.75
|
|
75
|
The significance of splenomegaly in 101 adults with acute lymphoblastic leukemia (ALL) at presentation and during remission.
|
Blood
|
1981
|
0.75
|
|
76
|
Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemia.
|
Cancer Chemother Pharmacol
|
1987
|
0.75
|
|
77
|
Fibroblast growth inhibitor.
|
Biomed Pharmacother
|
1988
|
0.75
|
|
78
|
Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia.
|
J Clin Oncol
|
1986
|
0.75
|
|
79
|
Treatment of advanced Hodgkin's disease with chemotherapy and irradiation. Controlled trial of two versus three alternating, potentially non-cross-resistant drug combinations.
|
Am J Med
|
1984
|
0.75
|
|
80
|
The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
|
Exp Hematol
|
1990
|
0.75
|
|
81
|
Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.
|
Leukemia
|
1992
|
0.75
|
|
82
|
Phase I trial of ImuVert (natural membrane vesicles associated with ribosomes) in patients with advanced cancer.
|
Cancer Immunol Immunother
|
1992
|
0.75
|
|
83
|
Kinetic response of human leukemic and lymphoma cells in vivo to combination chemotherapy using flow microfluorometry.
|
Cancer Treat Rep
|
1976
|
0.75
|
|
84
|
High-dose cytosine-arabinoside and mitoxantrone in refractory acute myeloid leukemia: a clinical phase I/II-study.
|
Onkologie
|
1986
|
0.75
|
|
85
|
Humoral-dependent hemopoiesis and flow cytometric analysis of chronic myelogenous leukemia in erythroblastic transformation.
|
Acta Haematol
|
1987
|
0.75
|